Targeted Epigenetic Therapy
In this video, Amin Nezami spends about 25 minutes speaking on "Targeted Epigenetic Therapy" at the 41st Annual Cancer Convention held on Labor Day weekend by the Cancer Control Society.
About Amin Nezami
AMIN NEZAMI, M.D. received his MD/Doctor of Medicine Degree from Tehran Medical I. Azad University in Iran in 1996. He completed his Residency in Family and Community Medicine at the University of California, San Francisco and an Internship in the Department of Surgery at the University California, Los Angeles. He is Board Certified in Family Medicine by the American Board of Fmily Medicine and he has been trained in Integrative Cancer Therapies, and is a Fellow and Diplomat with the American Academy of Anti-Aging and Regenerative Medicine.
He is an inventor of a new method of treating patients with a variety of cancers, both solid tumors and hematological cancers using natural substances, called MTET of multi-molecular targeted Epigenetic Therapy. Through this new method he has successfully treated patients with advanced cancer who have failed all other methods of conventional treatments. In collaboration with leading Oncology establishments in the academic settings, his method is on its way for broad spectrum clinical trials. His case stories have also been reviewed for best case series of Alternative and Complementary Medicine in oncology by the National Cancer Institute (NCI).
He is one of the Principal investigators commissioned by the National Institute of Health for the TACT Trial (Trial to Assess Chelation Therapy). His practice encompasses Integrative Oncology, Genetic Testing and Cancer Prevention and Treatment. His main area of research and interest is cancer stem cells and Epigenetic Plasticity And Differentiation Therapies.
Since 2008, he has been the Medical Director and President of Pacific Medical Center of Hope, in Fresno, California. This center has welcomed patients traveling from all over the US and as well as Europe. The second franchised center of his practice is opening in September 2013, in Newport Beach, California. He may be contacted through his Clinic by phone 559-475-4300. Please review his success stories on his website www.allcancercare.com.
Transcription
Good afternoon, everyone. As Frank mentioned, I have a passion about what is the most challenging problems of medicine, which is cancer. And the most challenging part in cancer I found to be genetics and the interaction of genes and what we call eppy genes or the environmental influence on the genes expression. As we go through the slides, you will see how I try to elaborate more scientifically about the interaction and how these genes are influenced, but not by what we call Eppy genes. Pretty much I am considered by others to be a scientist in this field, as that's my expertize. And during the last few years, I have developed a new protocol, as Frank mentioned, in treating patients with advanced cancer who mainly have failed the other modalities and conventional treatments. I gave a lecture this in this seminar in 2010, three years ago, and back then I was trying to squeeze in many of the science for integrative cancer therapies. Today, I try to be focused on that, on the topic and the subject of epigenetics. And obviously, if anybody has questions about other methods of treating cancer, including metabolic treatments that I do very commonly in my practice as well as immune therapies, you can always check the Web site. It's up there. W w. W. All cancer care. Dot com. HLL cancer care. Dot com. And I have some more information. Obviously I do consulting for other physicians. In fact, for someone, ecologists as well in patients who have failed their standard treatments. And I tried to come up with sort of a collaborative work with them to make sure that at the end of the day we have patients who fully respond to the therapy. And, you know, looking back in 2010 compared to now I was looking at the last three years and what's really conventional medicine has offered us in the sense of new treatments. In 2010 11, there were, as far as I remember, nine new cancer drugs come into the market that were approved by FDA. And in 2012, there were 16. Every day you have a new cancer therapy that a new drug that is approved by FDA. And these drugs mainly have been studied only once. And majority of these studies lack significant statistical strength. In fact, some of these studies are just done once outside the US and on a limited number of patients. But since the industry is desperate and the patients are dying more and more every day, the FDA is pushed by legislation to try to accommodate with new cancer therapies and try to approve any new drug in that sense. You